Internal Server Error

Aceragen - About the company

Aceragen is an acquired company based in Durham (United States), founded in 2021. It operates as a Developer of therapeutics for rare and orphan diseases. Aceragen has raised an undisclosed amount in funding. The company has 286 active competitors, including 77 funded and 98 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.

Company Details

Developer of therapeutics for rare and orphan diseases. The lead product of the company is ACG-801 a recombinant human acid ceramidase as an investigational therapy for Farber disease. Other products include ACG-701 for Melioidosis and cystic fibrosis and AGC-301 for cancer indications.
Social
XFacebook
Email ID
*****@aceragen.com
Registered Address
Exton, Pennsylvania
Key Metrics
Founded Year
2021
Location
Durham, United States
Stage
Acquired
Ranked
Annual Revenue
$1M - $10M as on Dec 31, 2022
Employee Count
23 as on Jul 01, 2024
Investment & Acquisitions
Similar Companies
Exit Details
Acquired

Aceragen's acquisition details

Aceragen got acquired on Sep 28, 2022.
Click here to take a look at Aceragen's acquisition in detail
Sign up to download Aceragen's company profile

Aceragen's funding and investors

Aceragen has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Jan 06, 2022 for $*****. 1 investor participated in its latest round. Aceragen has 2 institutional investors.

Here is the list of recent funding rounds of Aceragen:
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Jan 06, 2022
2420027
Grant (prize money)
6722649
5443086
4210426
3160917
lockAccess funding benchmarks and valuations. Sign up today!

Aceragen's founders and board of directors

Founder? Claim Profile

Aceragen's employee count trend

Aceragen has 23 employees as of Jul 24. Here is Aceragen's employee count trend over the years:
Employee count trend for Aceragen
lockUncover Aceragen's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Aceragen's Competitors and alternates

Top competitors of Aceragen include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Aceragen, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for BridgeBio
BridgeBio
2015, Palo Alto (United States), Public
Developer of therapeutics for the treatment of genetic diseases
$434M
82/100
2nd
Logo for Alnylam
Alnylam
2002, Cambridge (United States), Public
Developer of RNA interference-based therapeutics for multiple disorders
$17M
81/100
3rd
Logo for PTC Therapeutics
PTC Therapeutics
1998, South Plainfield (United States), Public
Developer of small molecule drugs for the treatment of rare diseases
$248M
73/100
4th
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
$84M
72/100
5th
Logo for Agios Pharmaceuticals
Agios Pharmaceuticals
2008, Cambridge (United States), Public
Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism
$120M
72/100
6th
Logo for Spark Therapeutics
Spark Therapeutics
2013, Philadelphia (United States), Acquired
Developer of gene therapy for rare diseases
$82.8M
69/100
7th
Logo for Ionis
Ionis
1989, United States, Public
Developer of RNA-targeted medicines for various diseases
-
69/100
8th
Logo for Alexion
Alexion
1992, Zurich (Switzerland), Acquired
Developer of therapies for patients with devastating and rare diseases
$133M
68/100
9th
Logo for Cabaletta Bio
Cabaletta Bio
2017, Radnor (United States), Public
Developer of CAAR T cells for B cell-mediated autoimmune diseases
$88.3M
68/100
10th
Logo for Regenxbio
Regenxbio
2008, Rockville (United States), Public
Developer of AAV Gene Therapy for rare genetic diseases
$108M
68/100
132nd
Logo for Aceragen
Aceragen
2021, Durham (United States), Acquired
Developer of therapeutics for rare and orphan diseases
-
38/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Aceragen's competitors? Click here to see the top ones

Aceragen's Investments and acquisitions

Aceragen has acquired Arrevus. Aceragen has not made any investments as of now.

Reports related to Aceragen

Here is the latest report on Aceragen's sector:

News related to Aceragen

•
Durham biotech startup Aceragen moves to liquidate assetsWRAL TechWire•Jul 13, 2023•Aceragen
•
Durham CEO now leads public company following acquisitionThe Business Journals•Sep 28, 2022•Aceragen
•
Aceragen Acquires Arrevus, Expands Late-Stage Rare Disease PipelineBioPharm International•Nov 03, 2021•Aceragen, Arrevus
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about Aceragen

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford